Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD By Ogkologos - November 7, 2025 252 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATHENA-MONO/GOG-3020/ENGOT-ov45 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Cómo pueden sobrellevar la ansiedad provocada por una exploración las personas... August 4, 2022 ASCO 2023 roundup: Blood tests, drugs and exercise June 12, 2023 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 Teen With Terminal Cancer Gives Make-A-Wish Gift To Other Kids In... December 4, 2019 Load more HOT NEWS Can Topical Drugs Help Prevent Breast Cancer? FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and... Happy Occupational Therapy Month Many Older Adults Screened Unnecessarily for Common Cancers
